I-131 MIBG THERAPY FOR NEUROBLASTOMA

I-131 MIBG 治疗神经母细胞瘤

• 批准号: 6308621
• 负责人: KATHERINE Kurshan MATTHAY
• 金额: $ 2.58万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6308621
• 关键词: child (0-11); clinical research; drug screening /evaluation; guanidines; halobenzene; human subject; human therapy evaluation; intravenous administration; iodine; neoplasm /cancer radionuclide therapy; neuroblastoma; pediatric neoplasm /cancer; pediatric pharmacology; radionuclides; radiopharmacology

131 I-MIBG is a norepinephrine analog that is concentrated in adrenergic tissues and therefore holds promise for cell-specific treatment of neuroblastoma, a lethal childhood tumor. The overall aim of this study is to determine the safety and efficacy of this targeted radioisotope for treatment of neuroblastoma. The study will test the hypothesis that targeted radiotherapy with 131 I-MIBG will produce responses in refractory neuroblastoma; and the major dose-limiting toxicity of 131 I-MIBG will be hematologic, it will be cumulative with successive doses, and can be managed by bone marrow or peripheral blood stem cell re-infusion.

131 I-MIBG是一种去甲肾上腺素类似物，集中在肾上腺素能组织中，因此有望用于神经母细胞瘤（一种致命的儿童肿瘤）的细胞特异性治疗。本研究的总体目的是确定这种靶向放射性同位素治疗神经母细胞瘤的安全性和有效性。该研究将检验以下假设：131 I-MIBG靶向放疗将在难治性神经母细胞瘤中产生反应; 131 I-MIBG的主要剂量限制性毒性将是血液学毒性，其将随着连续剂量而累积，并且可以通过骨髓或外周血干细胞再输注来管理。